ERBB2 and adenocarcinoma: Additionally, cost-reduction analysis revealed that CAD-CHM would only become a cost-effective first-line option for HER2-negative advanced G/GEJ adenocarcinoma in the overall population if the cost of cadonilimab (150 mg) dropped below $129.5.